Coherus Confirms Udenyca Launch And Brings In Chief Medical Officer

The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.

SiliconValley
Coherus, based in Silicon Valley, has just rolled out Udenyca in the US • Source: Shutterstock

Coherus BioSciences has launched its Udenyca (pegfilgrastim-cbqv) 6mg/0.6ml pre-filled syringes biosimilar to Amgen’s Neulasta in the US, matching the 3 January launch date promised by management upon US Food and Drug Administration (FDA) approval last November.

Days earlier, “biotechnology leader” Darlene Horton joined the California-based player as chief medical and regulatory affairs officer, lauding the “significant...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin